An in vitro Study for the Synergistic Cytotoxic Actions of Biological Therapy and Anticancer Chemotherapy Obayes Sarah K.1, Obied Hamid Naji1, Al-Saadi Mohammed A.K.1,* 1University of Babylon, College of medicine, Department of Pharmacology, Iraq *Corresponding author: Mohammed A.K. Al-Saadi. University of Babylon, College of medicine, Department of Pharmacology, Iraq, E-mail: mbmc.kadhum70@gmail.com
Online published on 17 July, 2019. Abstract Objective This study aimed to investigate the increase of the cytotoxic action of a minimal dose of anticancer chemotherapy (temozolomide) in combination with the biological therapy (interferon-alpha-2a). Seven in vitro experiments were used in this study. The cytotoxicity of temozolomide, interferon-alpha-2a and the combination of them was measured on melanoma B16 cell line for 24 and 48 hours incubation periods. The cells of these lines were seeded in 96-well plate. Temozolomide was used in a six serial dilutions (6.25, 12.5, 25, 50, 100, 200) μg/ml. Interferon-alpha-2a was also used in a six serial dilutions (37500, 75000, 125000, 250000, 500000, 1000000) IU/ml. The MTT(3-(4, 5-Dimethylthiazole-2-yl)-2, 5-diphenyl-2H-tetrazolium bromide) assay was used to determine the number of viable cells and the intensity of color was measured by ELISA reader. The combination of temozolomide and interferon-alpha-2a at 48 hours incubation period, there was a significant decrease (P≤ 0.05) in the viability percent of melanoma B16 cells for all concentrations of the combination therapy as compared to the control group. Top Keywords Temozolomide, interferon, cancer. Top |